
TRLV Stock Forecast & Price Target
TRLV Analyst Ratings
Bulls say
Trulieve Cannabis is supported by a medical-use thesis that has now been validated by DEA registrations issued to its state-licensed dispensaries in the first batch, confirming the framework around federal recognition of medical use and potential relief from 280E. Its scale and operating discipline stand out, with a highly automated 750K sq. ft. cultivation facility, a vertically integrated Florida platform of 162 dispensaries, and 2Q26 results showing $271M in revenue and $98M in EBITDA, both above consensus. The outlook remains constructive because core operations are outperforming while several incremental catalysts—Texas licensure, federal hemp restrictions, and broader regulatory reform—could add upside beyond current assumptions.
Bears say
Trulieve Cannabis is exposed to company-specific and industry-wide risks that weaken the investment case, including delayed regulatory approvals that could constrain expansion, state-level legislative and regulatory changes, and persistent competitive pricing pressure. Its heavy operational concentration in Florida adds another layer of vulnerability, because sales there typically weigh on total company revenue in 3Q as snowbirds leave the state during the warmer summer months, creating a predictable seasonal decline in demand. These pressures suggest that growth may be uneven and more fragile than the market might expect, with regulatory uncertainty and geographic concentration limiting visibility and profitability.
This aggregate rating is based on analysts' research of Trulieve Cannabis Corp and is not a guaranteed prediction by Public.com or investment advice.
TRLV Analyst Forecast & Price Prediction
Start investing in TRLV
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Trulieve Cannabis Corp (TRLV) Forecast
TRLV Analyst Forecast & Price Prediction
Start investing in TRLV
Order type
Buy in
Order amount
Est. shares
0 shares